Correlation Between SAB Biotherapeutics and Editas Medicine

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Editas Medicine at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Editas Medicine into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SAB Biotherapeutics and Editas Medicine, you can compare the effects of market volatilities on SAB Biotherapeutics and Editas Medicine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Editas Medicine. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Editas Medicine.

Diversification Opportunities for SAB Biotherapeutics and Editas Medicine

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between SAB and Editas is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Editas Medicine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Editas Medicine and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Editas Medicine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Editas Medicine has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Editas Medicine go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Editas Medicine

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 6.47 times more return on investment than Editas Medicine. However, SAB Biotherapeutics is 6.47 times more volatile than Editas Medicine. It trades about 0.06 of its potential returns per unit of risk. Editas Medicine is currently generating about 0.08 per unit of risk. If you would invest  7.53  in SAB Biotherapeutics on November 1, 2024 and sell it today you would lose (3.55) from holding SAB Biotherapeutics or give up 47.14% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

SAB Biotherapeutics  vs.  Editas Medicine

 Performance 
       Timeline  
SAB Biotherapeutics 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Editas Medicine 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Editas Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

SAB Biotherapeutics and Editas Medicine Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SAB Biotherapeutics and Editas Medicine

The main advantage of trading using opposite SAB Biotherapeutics and Editas Medicine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Editas Medicine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will offset losses from the drop in Editas Medicine's long position.
The idea behind SAB Biotherapeutics and Editas Medicine pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA